drugset / Trial / NCT03749148
Cholinergic Urticaria - Efficacy of Dupilumab
Phase 2
Completed
48 enrolled
Charite University, Berlin, Germany
Proinnovera GmbH · collabSanofi · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to assess the efficacy in reducing disease activity and safety of Dupilumab in adult patients with cholinergic urticarial (CholU) who are symptomatic despite H1-antihistamine treatment (licensed dose).
Timeline
- Start
- 2018-12-10
- Primary completion
- 2023-02-28
- Completion
- 2023-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dupilumab | Monoclonal antibody | 300 mg | Subcutaneous |